Lunai Bioworks has amended its employment agreement with CEO and director David Weinstein, cutting his annual salary and removing his contractual eligibility for severance and continued benefits if his employment ends. The revised agreement is effective from October 14, 2026, and sets December 28 as the expected end date unless the parties agree in writing to extend it.
Separately, Lunai has begun withdrawing its common stock from Nasdaq. The delisting was expected to take effect around November 12, 2026.
Key details
- Lower salary and shorter term: Weinstein’s annual base salary fell from $400,000 to $275,000 effective October 14. His employment is at will and, unless extended in writing, ends December 28.
- No automatic bonus or equity awards: He is not entitled to a bonus or equity award unless the board separately approves one.
- October pay deferred: His $28,150.68 base salary for October 2026 is to be paid in a lump sum, without interest, when his employment ends or on December 28, whichever comes first. Payment must be made no later than March 15, 2027.
- Severance and other termination protections waived: Weinstein gave up his prior rights to six months of base salary—about $200,000—continued benefits and accelerated equity vesting if terminated without cause or if he left for good reason. He also waived claims that the new terms themselves constitute good reason or breach the prior agreement.
- What remains payable if employment ends: For a termination for any reason, he is entitled only to earned but unpaid base salary and unreimbursed business expenses under the new agreement.
- Some prior rights remain intact: Compensation earned but unpaid before October 14, equity awards vested by that date, and his indemnification, expense-advancement and directors’ and officers’ insurance rights are preserved.
- Certain restrictions were removed: The prior non-competition and non-solicitation obligations ended. Confidentiality and invention-assignment obligations continue.
- Nasdaq withdrawal: Lunai filed to voluntarily withdraw its common stock from Nasdaq. The delisting was expected around November 12; withdrawal of the stock’s registration under the exchange-listing provisions was expected to become effective 90 days after the company’s November 2 filing.
The revised agreement reduces Lunai’s contractual salary commitment to Weinstein and eliminates specified severance and benefit obligations. The Nasdaq withdrawal is a separate change affecting where the company’s shares are listed.
